UNSPSC 51172151: Tiropramide or tiropramide hydrochloride

This classification denotes a parasympatholytic and tyrosine analog with the molecular formulas C28H41N3O3 and C28H41N3O3.ClH, preparations that US FDA regulates as active ingredients or moieties under Unique Ingredient Identifiers R7S0904CN2 and 9523013Y6R, the base compound being chemically known as dl-alpha-benzamido-para-(2-(diethylamino)ethoxy)-n,n-dipropylhydrocinnamamide but generally known as tiropramide, which bears US NIH Compound Identifier 42262.

UNSPSC 51172151 Tiropramide or tiropramide hydrochloride is a Commodity code covering a specific pharmaceutical active ingredient; however, the recent state and local contract opportunities tagged to this code do not solicit tiropramide itself. Instead, the code shows minimal relevant procurement activity. The three most recent opportunities include a Collin County Community Supervision and Corrections Department RFP for offender drug testing services (which specifies immunoassay screening, LC/MS/MS, and GC/MS confirmation but does not name tiropramide as a test component), a Texas Health and Human Services Commission RFI on direct-to-manufacturer prescription programs (a market intelligence exercise on pharmacy benefit models with no specific drug products identified), and a Minnesota Multistate Cooperative Purchasing Alliance RFP for generic multi-source pharmaceuticals and OTC products distributed through authorized wholesalers (which solicits broad pharmaceutical categories without reference to tiropramide). The mismatch between the code's nominal scope and the actual work being solicited suggests that this code carries minimal recent state and local demand for tiropramide specifically.

The geographic footprint of recent activity spans Texas and Minnesota, with the Collin County opportunity representing the most concrete and immediately actionable solicitation (RFP 2026-327, due July 23, 2026, estimated contract value $600,000 over two years with three optional one-year renewals). However, that RFP addresses specimen collection and drug testing infrastructure rather than tiropramide procurement. The Minnesota MMCAP RFP (due March 26, 2026, with award effective July 1, 2026) covers generic pharmaceuticals across multiple state and local facilities but does not isolate tiropramide demand. State and local governments appear to be procuring pharmaceutical products and testing services through broad cooperative purchasing vehicles and specialized criminal-justice testing programs, but tiropramide itself does not surface as a discrete procurement line item in recent opportunities.